FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Alfredo Falcone, Silvia Mezi et al.|The Lancet Oncology|2015Cited by 1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal CancerFotios Loupakis, Alfredo Falcone, Chiara Cremolini et al.|New England Journal of Medicine|2014Cited by 1.1k
Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)Michelino De Laurentiis, Grazia Arpino, Luca Malorni et al.|Cancer Research|2020Cited by 6